U.S. Markets close in 5 hrs 12 mins

Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

-- Boys on Edasalonexent Grew More than Two Inches Taller per Year on Average --

Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today shared additional clinical results from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, boys with Duchenne muscular dystrophy (DMD) treated with edasalonexent on average grew in line with the growth of unaffected boys in the same age range. These data were presented on Sunday, February 17, 2019, at the XVII International Conference on Duchenne and Becker Muscular Dystrophy in Rome, Italy.

“While the primary goal in treating boys with Duchenne is to slow the progression of the disease, we recognize the significant negative impact on boys’ quality of life when they do not grow and develop like their friends. We are pleased to see boys on edasalonexent growing like their unaffected peers while also demonstrating substantially slowed disease progression,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis. “These characteristics are what make edasalonexent a great potential foundational therapy for the treatment of Duchenne.”

In the MoveDMD trial, boys treated with edasalonexent grew an average of 2.1 inches taller per year and gained 2.9 pounds per year, and their overall body mass index decreased from 70th percentile of unaffected boys to the 55th percentile over 72 weeks of treatment, approaching the average body mass index for unaffected boys. Boys treated with corticosteroids, the standard of care in DMD, typically experience excess weight gain and curtailed growth.

“Using corticosteroids can be very beneficial to many patients with DMD. However, alternatives are desperately needed as steroids come with a long list of very unpleasant side effects, which includes stunted growth. This can affect self-esteem and confidence. We are very encouraged by this early data suggesting that boys on edasalonexent did not have their growth affected, and we look forward to seeing more results,” said Emily Crossley, co-founder and co-CEO, Duchenne UK.

Edasalonexent is being studied in the Phase 3 PolarisDMD trial, which is actively enrolling patients. The PolarisDMD trial is evaluating the efficacy and safety of edasalonexent in patients with DMD and is intended to support an application for commercial registration of edasalonexent. A total of 17 PolarisDMD clinical trial sites are now open for enrollment across the United States, Canada and Australia. Additional PolarisDMD clinical trial sites are expected to open in the United States, Canada, Europe, Australia and Israel in the next couple of months. In total, the PolarisDMD trial will include approximately 40 clinical trial sites globally with enrollment expected to be completed in 2019.

The global Phase 3 PolarisDMD trial is a one-year, randomized, double-blind, placebo-controlled trial. Catabasis plans to enroll approximately 125 patients ages 4 to 7 (up to 8th birthday) regardless of mutation type who have not been on steroids for at least 6 months. Boys on a stable dose of eteplirsen may be eligible to enroll. The primary efficacy endpoint is change in the North Star Ambulatory Assessment score after 12 months of treatment with edasalonexent compared to placebo. Key secondary endpoints include the age-appropriate timed function tests: time to stand, 4-stair climb and 10-meter walk/run. Assessments of growth, cardiac and bone health are also included as important potential areas of differentiation. Two boys will receive 100 mg/kg/day of edasalonexent for each boy that receives placebo, and, after 12 months, all boys are expected to receive edasalonexent in an open-label extension study. The PolarisDMD trial design was informed by discussions with regulators as well as input from treating physicians, patient organizations and families of boys affected by Duchenne.

The Phase 3 PolarisDMD trial is designed to further validate the positive efficacy seen in the MoveDMD Phase 2 trial and open-label extension evaluating edasalonexent. In the MoveDMD trial, we observed that edasalonexent preserved muscle function and substantially slowed DMD disease progression across all four assessments of muscle function (the North Star Ambulatory Assessment, time to stand, 4-stair climb and 10-meter walk/run) through 72 weeks of treatment compared to an off-treatment control period. Preclinical data and clinical biomarker data from the MoveDMD Phase 2 trial suggest that edasalonexent could have potential benefits in skeletal muscle, diaphragm and heart. Edasalonexent has been well tolerated through more than 55 patient-years of treatment with no safety signals observed.

More information about the Phase 3 PolarisDMD clinical trial is available on clinicaltrials.gov and in a recently recorded webinar with PPMD. Contact the Catabasis clinical team with any questions at DMDtrials@catabasis.com.

About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential new standard of care for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-kB, which is a key link between loss of dystrophin and disease progression in DMD. NF-kB has a fundamental role in skeletal and cardiac muscle disease in DMD. We are currently enrolling our global Phase 3 PolarisDMD trial to evaluate the efficacy and safety of edasalonexent for registration purposes. In our MoveDMD Phase 2 trial and open-label extension, we observed that edasalonexent preserved muscle function and substantially slowed disease progression compared to rates of change in a control period, and significantly improved biomarkers of muscle health and inflammation. Edasalonexent continues to be dosed in the open-label extension of the MoveDMD trial. The FDA has granted orphan drug, fast track, and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results, please visit www.catabasis.com.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.

Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about future clinical trial plans including, among other things, statements about the Company’s global Phase 3 PolarisDMD trial in DMD to evaluate the efficacy and safety of edasalonexent for registration purposes, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s product candidates; and general economic and market conditions and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190219005230/en/

  • Is Snap Stock A Buy Right Now? Here's What Earnings, Charts Show
    Business
    Investor's Business Daily

    Is Snap Stock A Buy Right Now? Here's What Earnings, Charts Show

    Snap has recovered from a steep decline that began the day after its initial public offering in 2017. It took a long time, but a series of product upgrades added to the company's Snapchat messaging platform are driving Snap stock to new highs. Snap stock has more than tripled from its record low of 4.82 in December and moved into a buy zone on Friday.

  • Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 20%
    Business
    TipRanks

    Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 20%

    Let's start with some good news – according to Goldman Sachs' chief global equity strategist Peter Oppenheimer, 2020 will see a continuation of last year's surge. Oppenheimer believes 2019's bull run was down to valuation expansion. With this in mind, we decided to have a look at two stocks Goldman Sachs thinks are poised to make headway in 2020.

  • U.S.
    Financial Times

    Could new regulation spell the death of trusts?

    p These days trusts are often used in wills for estate planning and are frequently combined with life assurance policies. They also feature in inheritance tax planning because they allow people to control how their assets are used after they have given them away.

  • 3 “Strong Buy” Stocks for the 5G Revolution in 2020
    Business
    TipRanks

    3 “Strong Buy” Stocks for the 5G Revolution in 2020

    Investors in Tower Semiconductor stock can expect to see "low double-digit" organic growth in 2020, says Needham analyst Rajvindra Gill. And while that may not sound like much, it's significantly faster -- potentially as much as twice as fast -- as the 6.7% growth rate that most Wall Street analysts are expecting (which could mean additional upgrades will follow as Tower delivers on its promises). Tower aims to aggressively expand capacity at its factories churning out 200mm and 300mm chips to supply growing demand for 5G smartphones, which are experiencing "stronger than expected 5G proliferation."

  • Aurora Cannabis jumps as analysts get bullish
    Business
    Yahoo Finance Video

    Aurora Cannabis jumps as analysts get bullish

    Aurora's stockis climbing as Cowen expects the cannabis company to focus on controlling capital spending and restructuring its debt. Yahoo Finance's Emily McCormick joins Seana Smith on The Ticker to discuss.

  • What to Do After Maxing Out Your 401(k) Plan
    Business
    Investopedia

    What to Do After Maxing Out Your 401(k) Plan

    "Through the use of policy loans, you may be able to take money out without paying taxes and put the money back in without paying taxes, as long as the life insurance policy is kept in force." The owner must pay tax on gains if the policy is canceled. Riskier Options There are some directions you can take if you still have a solid income or are expecting a windfall in the near future.

  • U.S. will look at sudden acceleration complaints involving 500,000 Tesla vehicles
    U.S.
    Reuters

    U.S. will look at sudden acceleration complaints involving 500,000 Tesla vehicles

    The National Highway Traffic Safety Administration (NHTSA) said Friday it will review a petition asking the agency to formally investigate 500,000 Tesla Inc vehicles over sudden unintended acceleration reports. The petition covers 2012 through 2019 model year Tesla Model S, 2016 through 2019 Tesla Model X, and 2018 through 2019 Tesla Model 3 vehicles, the agency said. The petition cites "127 consumer complaints to NHTSA involving 123 unique vehicles.

  • The last time this ‘clear danger sign’ flashed in the stock market was in 1999, and we all know what happened next
    Business
    MarketWatch

    The last time this ‘clear danger sign’ flashed in the stock market was in 1999, and we all know what happened next

    The chart, pulled from a recent Wall Street Journal story, essentially shows how much red ink is spilling in the IPO market. As you can see, the last time this “clear danger sign” popped up was on the brink of the dot-com implosion in 1999. As the Journal pointed out, 42% of these money-losers come from the health-care sector, where investors look to make a killing on smaller biotech stocks with big upside.

  • Does Coeur Mining's (NYSE:CDE) Share Price Gain of 58% Match Its Business Performance?
    Business
    Simply Wall St.

    Does Coeur Mining's (NYSE:CDE) Share Price Gain of 58% Match Its Business Performance?

    For example, the Coeur Mining, Inc. (NYSE:CDE) share price is up 58% in the last year, clearly besting the market return of around 23% (not including dividends). Because Coeur Mining made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth.

  • Calculating The Intrinsic Value Of Tilray, Inc. (NASDAQ:TLRY)
    Business
    Simply Wall St.

    Calculating The Intrinsic Value Of Tilray, Inc. (NASDAQ:TLRY)

    In this article we are going to estimate the intrinsic value of Tilray, Inc. (NASDAQ:TLRY) by taking the expected future cash flows and discounting them to today's value. We generally believe that a company's value is the present value of all of the cash it will generate in the future. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

  • Fourth person pleads guilty in $1 billion solar energy scam
    U.S.
    MarketWatch

    Fourth person pleads guilty in $1 billion solar energy scam

    An executive of a San Francisco Bay Area solar energy company pleaded guilty Tuesday to participating in what federal prosecutors said was a massive Ponzi scheme that defrauded investors of $1 billion. Ryan Guidry, 43, of Pleasant Hill entered pleas involving the scam and money laundering. Guidry was vice president of operations for DC Solar, based in Benicia, northeast of San Francisco.

  • Stryker Corporation's (NYSE:SYK) 1.1% Dividend Yield Looks Pretty Interesting
    Business
    Simply Wall St.

    Stryker Corporation's (NYSE:SYK) 1.1% Dividend Yield Looks Pretty Interesting

    Dividend paying companies with growing earnings can be highly rewarding in the long term. If you are hoping to live on your dividends, it's important to be more stringent with your investments than the average punter. Regular readers know we like to apply the same approach to each dividend stock, and we hope you'll find our analysis useful.

  • Jack Dorsey Asks Elon Musk How to Fix Twitter
    Business
    Bloomberg

    Jack Dorsey Asks Elon Musk How to Fix Twitter

    Musk, the SpaceX and Tesla Inc. chief executive officer, was asked Thursday by Twitter Inc. CEO Jack Dorsey how he would fix the social network, where Musk has almost 31 million followers. “Give us some direct feedback,” said Dorsey, who spoke to Musk via a video call from a company meeting in Houston. Musk was projected onto a giant screen as thousands of Twitter employees watched the two executives chat.

  • Retirement Planning Tips if You're in Your Mid-60s and Beyond
    Business
    Investopedia

    Retirement Planning Tips if You're in Your Mid-60s and Beyond

    Retirement planning at any age can be challenging. Still, there are certain steps to take when you're in your mid-60s and beyond to make sure you're ready for those golden years. At one time, the common age for retirement was 65, but times have changed.

  • Business
    U.S.News & World Report

    15 of the Best Dividend Stocks to Buy for 2020

    Each offers the potential for capital appreciation and yields that 10-year Treasurys can't provide. Pharmaceutical giant Bristol-Myers Squibb, fresh off a year in which it gobbled up "pharma tour de force" Celgene and gained 28%, looks like one of the best dividend stocks to buy for 2020. The best dividend stocks to buy are often ones that can both afford to pay shareholders a meaningful quarterly dividend -- preferably a sustainable and growing one -- and offer a shot at solid capital gains.

  • These 13 Tempting Dividend Stocks Torched Investors
    Business
    Investor's Business Daily

    These 13 Tempting Dividend Stocks Torched Investors

    Investors wound up losing money despite each of these stocks yielding 3% at the start of 2019 — because the stocks themselves plummeted. The SPDR S&P 500 ETF Trust, in comparison, started 2019 yielding just 2.01% (it's down to 1.7% now). Losing money especially stung in 2019, when the S&P 500 rose nearly 29%.

  • U.S.
    TheStreet.com

    Is the Stock Market Open on Martin Luther King Jr. Day?

    Martin Luther King Jr. Day was first signed into law in 1983, and first officially observed as a holiday in 1986. Generally observed on the third Monday of January (close to or on King's actual birthday, January 15), MLK Day celebrates the life and legacy of one of America's most well-known and influential activists, who fought for racial and economic justice across the country. Martin Luther King Jr. Day, falling on January 20 this year, is a federal holiday, and not every worker in the country necessarily gets a day off of work for it (45% of employers gave workers the day off in 2019).

  • Facebook sued to force Zuckerberg to give up control
    Business
    Yahoo Finance Video

    Facebook sued to force Zuckerberg to give up control

    Four tech firms are suing Facebook in an attempt to get CEO Mark Zuckerberg to relinquish control of the company and sell his majority stake. Yahoo Finance's Dan Howley joins Dan Roberts and Seana Smith on The First Trade to discuss.

  • Business
    TheStreet.com

    Qualcomm Climbs on Upgrade to Buy at Citigroup

    Qualcomm advanced 1.2% to $92.92 in premarket trading Friday after a Citi analyst upgraded shares of the semiconductor maker to buy from neutral. Analyst Christopher Danely also raised his price target on the stock of the San Diego-based company to $108 from $89. In a note to investors, Danely said the "long-awaited 5G ramp" was starting to come together this year, adding that Qualcomm is "one of the most exposed stocks to 5G" and 2020 will "be the year where the company experiences accelerating revenue and EPS growth driven by the beginning of the 5G upgrade cycle."

  • Afraid of sky-high stock valuations? These ‘Dividend Aristocrats’ have yields over 3%
    Business
    MarketWatch

    Afraid of sky-high stock valuations? These ‘Dividend Aristocrats’ have yields over 3%

    Dividend Aristocrats The S&P Dividend Aristocrats (XX:SP50DIV) are companies that have raised their regular dividend payouts consistently. The group as a whole tends to be considered a growth investment, because many of the dividend yields are low and the group has outperformed the broader market over very long periods. But today we're going to focus on current income by simply listing the Aristocrats with the highest dividend yields.

  • The Federal Reserve is stuck in quantitative-easing hell
    Business
    MarketWatch

    The Federal Reserve is stuck in quantitative-easing hell

    Since September, the central bank, through the Federal Reserve Bank of New York, has been purchasing securities hand over fist to alleviate short-term pressures in the overnight money markets. It has used repurchase (“repo”) and reverse repurchase (“reverse repo”) agreements to provide liquidity and keep overnight borrowing rates from spiking. But these complex money market operations already have caused the Fed to buy a net $400 billion worth of securities, after Chairman Jerome Powell shrank the Fed's balance sheet by $700 billion.

  • AT&T's Breakout Level to Watch
    Business
    TheStreet.com

    AT&T's Breakout Level to Watch

    AT&T is gearing up for earnings at the end of the month - when the telecommunications and media company reports its numbers in a week or so, analysts are looking for earnings of about 87 cents a share. At a glance, AT&T has been a great example of an outperforming blue-chip name: Shares have posted total returns of 31.4% in the trailing 12 months, beating the rest of the S&P 500 in the process. On the surface, it might look like AT&T's momentum is stalling.

  • Business
    Barrons.com

    A GE Critic Says the Stock Price Is Wrong. But President Trump Has Hope.

    GE stock (ticker: GE) recently traded at $11.92 on Thursday, up about 0.4% for the day, while the Dow Jones Industrial Average and the S&P 500 were up 0.6%. “A key difference between our negative stance and a more positive consensus is that we view the deterioration in fundamentals at GE as reflecting structural challenges versus something more cyclical,” Tusa writes. “He'll straighten it out,” Trump added, referring to Peltz.

  • Nine High Dividend Stocks You Can Count On
    Business
    Investor's Business Daily

    Nine High Dividend Stocks You Can Count On

    It's easy to chase high dividend stocks — and even easier to lose money on them if they fall. There's a better way to find high dividend yields you can count on to make you money — which includes stocks like REIT Store Capital, a slew of banks like PNC Financial and pet pharmacy PetMed Express. What's an investor looking for high dividend stocks to do then?

  • Did You Manage To Avoid Agenus's (NASDAQ:AGEN) 22% Share Price Drop?
    Business
    Simply Wall St.

    Did You Manage To Avoid Agenus's (NASDAQ:AGEN) 22% Share Price Drop?

    It is doubtless a positive to see that the Agenus Inc. (NASDAQ:AGEN) share price has gained some 47% in the last three months. In fact, the share price is down 22%, which falls well short of the return you could get by buying an index fund. Agenus wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS).